Li Fraumeni syndrome: A case with multiple primary cancers and presenting a germline p53 mutation;Le syndrome de Li Fraumeni: à propos d'un cas familial avec cancers multiples et présentant une mutation germinale du gène p53

Annales de Biologie Clinique

Volumn 68, Issue 3, 2010, Pages 346-350

  Landolsi, Sondess ^a   Gharbi, Olfa ^a   Zrig, Makram ^b   Gribaa, Moez ^a   Njim, Leila ^b   Zakhama, Abdelfattah ^b   Abid, Abderrazek ^b   Frébourg, Thierry ^c   Ahmed, Slim Ben ^a  

^a FARHAT HACHED HOSPITAL   (Tunisia)

^b FATTOUMA BOURGUIBA UNIVERSITY HOSPITAL   (Tunisia)

^c ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

Genetic disease; Genetics; Li Fraumeni syndrome genetic disease; Multiple cancer; Mutation; P53

Indexed keywords

ADULT; ARTICLE; CASE REPORT; FAMILIAL CANCER; FATALITY; GENETICS; HUMAN; MALE; MUTATION; PEDIGREE; TUMOR SUPPRESSOR GENE;

ADULT; FATAL OUTCOME; GENES, P53; GERM-LINE MUTATION; HUMANS; LI-FRAUMENI SYNDROME; MALE; PEDIGREE;

EID: 77952842607     PISSN: 00033898     EISSN: 19506112     Source Type: Journal    
DOI: 10.1684/abc.2010.0441     Document Type: Article

References (31)

1. Tena Sanabria ME, Herrera Sánchez D, Hernández López J, Huicochea Montiel JC, Rodríguez A. Li Fraumeni syndrome familial cancer case report and literature review. Acta Orthoped Mexic 2007; 21: 99-104.
2. Li FP, Fraumeni Jr JF, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, et al. A cancer family syndrome in twenty-four kindreds. Cancer Res 1988; 48: 5358-5362
3. Birch JM, Hartley AL, Tricker KJ, Prosser J, Condie A, Kelsey AM, et al. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 1994; 54: 1298-1304
4. Chompret A, Abel A, Stoppa-Lyonnet D, Brugières SL, Pagès S, Feunteun J, et al. Sensitivity and predictive value of criteria for p53 germline mutation screening. J Med Genet 2001; 38: 43-47
5. Li FP, Fraumeni JF. Soft tissue sarcomas, breast cancer, and other neoplasms: a familial syndrome ? Ann Intern Med 1969; 71: 747-752
6. Li FP, Fraumeni JF, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, et al. A cancer family syndrome in 24 kindreds. Cancer Res 1988; 48: 5358-5362
7. Malkin D, Li FP, Strong LC, Fraumeni JF, Nelson CE, Kim DH, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms. Science 1990; 250: 1233-1238
8. Varley JM, McGown G, Thorncroft M, Santibanez-Koref MF, Kelsey AM, Tricker KJ, et al. Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families. Cancer Res 1997; 57: 3245-3252
9. Birch JM, Alston RD, McNally RJ, Evans DG, Kelsey AM, Harris M, et al. Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene 2001; 20: 4621-4628
10. Bougeard G, Limacher JM, Martin C, Charbonnier F, Killian A, Delattre O, et al. Detection of 11 germline inactivating TP53 mutations and absence of TP63 and HCHK2 mutations in 17 French families with Li-Fraumeni or Li-Fraumeni-like syndrome. J Med Genet 2001; 38: 253-256
11. Bougeard G, Sesboue R, Baert-Desurmont, Vasseur S, Martin C, Tinat J, et al. Molecular basis on the Li-Fraumeni syndrome: an update from the French LFS families. J Med Genet 2008; 45: 535-538
12. Gonzalez KD, Noltner KA, Buzin CH, Gu D, Wen-Fong CY, Nguyen VQ, et al. Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. JCO 2009; 27: 1250-1256
13. Lefrou L, Godart B, De Muret A, Scotto B, Dorval E. Néomutation germinale du gène p53 chez un malade présentant un syndrome de Li-Fraumeni et un adénocarcinome du pancreas. Gastro Enter Clin Biol 2006; 30: 484.
14. Agir H, Mackinnom C, Tan S. Li-Fraumeni syndrome: a case with 4 separate primary sarcomas and 5 sequential free flaps in the maxillofacial region. J Oral Maxillofac Surg 2008; 66: 1714-1719
15. Johanson SL, Cohen SM. Epidemiology and etiology of bladder cancer. Semin Surg Oncol 1997; 13: 291-298
16. Dimenza L, Bourou JC, Vieillefond A, Chondot D, Boccon Gibod L, Zummer K. Facteurs de risques des tumeurs de vessie; étude épidé miologie chez 701 sujets en Île-de-France. Press Med 1991; 20: 1436-1439
17. Haleblian E, Skinner C, Dickinson G, Lieskovsky G, Skinner G. Hydronephrosis as a pronostic indicator in bladder cancer patients. J Urol 1998; 160: 2011-2014
18. Melicow MM. Tumors of the bladder: a multifaceted problem. J Urol 1974; 112: 467-478
19. Aboutaieb R, Dakir M, Sarf I, Meziane F, Benjelloun S. Les tumeurs de vessie chez le jeune. Prog Urol 1998; 8: 43-46
20. Ghnassia JP, Wagner M, Velten M. Les tumeurs stromales du tube digestif: evaluation prognostique d'une série de 36 cas. Ann Pathol 1996; 16: 27-32.
21. Olivier M, Goldgar DE, Sodha N, Ohgaki H, Kleihues P, Hainaut P, et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res 2003; 63: 6643-6650
22. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994; 265: 346-355
23. Birch JM, Blair V, Kelsey AM, Evans DG, Harris M, Tricker KJ, et al. Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome. Oncogene 1998; 17: 1061-1068
24. Chompret A. The Li-Fraumeni syndrome. Biochimie 2002; 84: 75-82.
25. Vahteristo P, Tamminen A, Karvinen P, Eerola H, Eklund C, Aaltonen LA, et al. p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition. Cancer Res 2001; 61: 5718-5722
26. Evans SC, Lozano G. The Li-Fraumeni syndrome: an inherited susceptibility to cancer. Mol Med Today 1997; 3: 390-395
27. Expertise collective Inserm. Risques héréditaires de cancers du sein et de l'ovaire. Quelle prise en charge ? Paris: Inserm, 1998.
28. Frebourg T, Abel A, Bonaiti-Pellie C, Brugières L, Berthet P, Bressac-de Paillerets B, et al. Le syndrome de Li-Fraumeni: mise au point, données nouvelles et recommandations pour la prise en charge. Bull Cancer 2001; 88: 581-587 (Pubitemid 32678350)
29. Varley JM. Germline TP53 mutations and Li-Fraumeni syndrome. Hum Mutat 2003; 21: 313-320
30. Asciari S, Van den Abbeele AD, Diller LR, Rastarhuyeva I, Yap J, Schneider K, et al. Fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li-Fraumeni syndrome. JAMA 2008; 299: 1315-1319
31. Senzer N, Nemunaitis J, Nemunaitis M, Lamont J, Gore M, Gabra H, et al. P53 therapy in a patient with Li-Fraumeni syndrome. Mol Cancer Ther 2007; 6: 1478-1482